Blog search results for Tag: BrightSCIdea

Science & Innovation

Six teams have made it to the exciting final of this year’s Bright SCIdea Challenge.

The Bright SCIdea Challenge sees university students develop an innovative science-based idea into a business plan - and then to compete for a £5,000 prize.

SCI supports entrants during the competition by delivering free, exclusive training, and the teams with the strongest business plan are invited to deliver their pitch to an expert panel of experienced, successful senior business people and innovators.

The first Bright SCIdea challenge took place in March 2018 and since then the competition has seen winners go on to launch companies, raise significant funding and take their products to market.

This year’s final - the seventh instalment of SCI’s annual entrepreneurship competition - takes place at SCI’s headquarters on March 17.


Here are the 2026 Bright SCIdea Challenge finalists:

Ascenx

Ascenx

Sophie Siu, William Wang, Justin Wong and Gwen Rico

Where are they from?
University College London

Why did they enter the Bright SCIdea Challenge 2026?
“As second year chemistry students we were keen to apply our theoretical knowledge to a viable business idea under the guidance of industry experts in a fun and dynamic setting. Our entry was catalysed by reading a paper by Kaifeng Wang and Case M. van Genuchten which discussed a novel process of retrieving arsenic from wastewater sludge. We were fascinated by the chemistry and its dual potential of ensuring clean drinking water whilst supplying a sustainable arsenic source. The opportunity to contribute to a meaningful global impact strongly aligned with our humanitarian values and motivated us to participate.”


AvennaX

Avennax - BrightSCIdea finalists 2026

Josh Das, Peilin Chen and Tara Hudson-Ballard

Where are they from?
Imperial College London

Why did they enter the Bright SCIdea Challenge 2026?
“We entered the BrightSCIdea challenge to accelerate the commercial scaling of AlphaSuite, build a network of other scientific innovators, and gain mentorship from experts. This competiton offers the opportunity to develop our roadmap for market entry, ensuring our innovation is positioned for long term growth. Winning would provide the foundational funding for us to scale our technical infrastructure and secure our IP, and the insights gained from this experience will help us turn our innovation into a successful venture truly valuable to the global research and healthcare community.”


CheGo

CheGo - Bright SCIdea finalists 2026

Cheyenne Gracias, Chayanit Panjak, Hita Dunukunala and Yunseo Lee

Where are they from?
Kings College London

Why did they enter the Bright SCIdea Challenge 2026?
“Having previously won a hackathon, our team believes real impact comes from bringing solutions to industry which is why BrightSCIdea felt like the right next step. Our inspiration came from a teammate's mother, an experienced ICU nurse, who described how suctioning can cause bleeding and stress for patients and nurses. This sparked our add-on sensor system that transforms standard closed suction catheters into precision-guided medical devices, reducing complications in intensive care. Beyond technical skills, we recognised the need for commercialisation expertise. This competition offers industry feedback, workshops, and funding to develop our prototype into a real product.”


MediKeto

Mediketo - BrightSCIdea Finalists 2026

Nano Kojima, Yuri Fujikura and Eleina Hames

Where are they from?
Institute of Science Tokyo

Why did they enter the Bright SCIdea Challenge 2026?
“The ketogenic diet is a highly evidence-based treatment for drug-resistant epilepsy, yet it remains underutilised because of the daily management burden. We built MediKeto to change that.

"As an early-stage team bridging medicine and engineering, the Bright SCIdea Challenge offers something distinct: international validation, critical feedback and support from industry experts, and funding that would directly accelerate our pathway from healthcare app to SaMD. We are determined to refine our concept and empower patients and families who need it most, ultimately boosting treatment adherence and unlocking a better quality of life.”


Napré

Napre - BrightSCIdea finalists 2026

Nwachukwu Christiana Okonkwo, Kosisochukwu Judith Offojebe, Ikwuezuma Elochukwu Reynolds and Ekeomodi Chikodi Christabel

Where are they from?
Newcastle University, McGill University, Nnamdi Azikiwe University and Stellenbosch University

Why did they enter the Bright SCIdea Challenge 2026?
“Our participation in Bright SCIdea challenge was driven by our identification of a critical gap in the manufacturing industry: while billions are spent producing drug and food products, the adverse effects of the preservatives used in these products have been largely neglected. We saw an opportunity to change the status quo and create a paradigm shift to safer preservatives while protecting the environment - through the valorisation of agricultural waste. Bright SCIdea offers us an opportunity to connect with visionary partners who share our goal: to disrupt a dysfunctional market with innovative solutions that promote well-being without sacrificing commercial value.”


QROOT — Quantum Reactive Optical Observation of Terrain

Qroot - BrightSCIdea finalists 2026

Gergo Meszaros, Hassan Raza Khan and Kaden Ethan Tan

Where are they from?
University of Toronto and Brown University

Why did they enter the Bright SCIdea Challenge 2026?
“Uncertainty. Corporations cannot always predict crop yields or the best interventions. Farmers cannot know whether fields will suffer from disease or deplete prior to the first harvest—yet they plant, nurture, and persevere anyway. If they can act despite uncertainty, why shouldn't we? The practicality of scaling a business, of turning innovation into impact, and reaching those who need it most was unknown to us—but because they try, we must too. With BrightSCIdea we have our expertise, the guidance of industry experts, and the network to bring QROOT to life, that is why we are here.”

Careers

In the second part of our chat with Bright SCIdea finalist Team Eolic Wall, we found out how they prepared for their presentation and judges’ questions, and what’s next for their innovative wind turbine technology.

The road from Eureka moment to finished product is paved with peril. Team Eolic Wall’s idea for small, modular wind turbines that use magnetic levitation to harness more power than existing turbines could bring wind power generation into our very homes. But bringing a groundbreaking product to market is not just about mastering the science. It must make business sense too.

As with the other Bright SCIdea hopefuls, Team Eolic Wall received free training from SCI in the form of online tutorials from experienced professionals including modules on structuring a business, financial modelling, branding, and marketing.

Eolic wall

After completing the training, Eolic Wall rose to meet the challenge. The team qualified for the Bright SCIdea final and, with it, the pivotal presentation in front of a live audience and panel of expert judges.

Many of us take it as a given that we speak to people at work in our native tongue. The nuances of communication – the cultural subtleties and oddities of the English language – aren’t a concern. But Team Eolic Wall had to present in their second language.


Pitch perfect?

‘This was not our first international presentation, but it was the first one in a foreign language,’ said Alfredo Calle, Eolic Wall founder, ‘so that's always a little bit intimidating until one gets used to it.’

The key to them nailing the pitch was in the spade-work. Calle and his colleagues rehearsed the speech until they knew it by heart. ‘It’s all about training and preparation,’ he said. ‘The more you rehearse, the more confident you feel when the presentation moment comes.’

 

Of course, the presentation is predictable but the judges’ questions are less so. Having undergone the rigours of competition, Calle recommends that this year’s entrants prepare by trying to predict the types of questions they will be asked. A cold rehearsal could help with the potentially stunning situation of someone throwing questions at you from strange angles.

That team Eolic Wall presented its technology online made theirs even trickier still, especially given a technical hitch at the beginning. But they had polished the presentation to a smoothness that offset such difficulties and came away as joint winners of the Audience Award.

The only lingering regret for them was that Covid prevented them from coming to London. ‘We wish we could have made it to the final,’ he said. ‘Facing the judges and audience live would have been a tremendously valuable and enriching experience.’


A wind energy democracy

Since the Bright SCIdea final, the Eolic Wall is being built brick by brick. The team has received three grants in recent months including one from ProCiencia, the largest innovation agency of the Peruvian government.

Eolic wall
Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.

However, perhaps the most exciting development is the technology itself. ‘We have accomplished a peripherally supported wind turbine that works with magnetic levitation,’ Calle said. ‘That's a huge milestone that makes us believe we are building something big.’

Calle hopes for more investment to develop the technology further. At heart, he believes the Eolic Wall will give regular people the chance to generate affordable wind energy from home.

‘We are working out a solution to democratise wind energy for the sake of this blue rock we call home.’

>> Find out how Team Eolic Wall’s innovative technology in part 1 of this blog.


Careers

Imagine owning a small wind turbine that generates all of your home’s energy needs. As the clock counts down on entries for for the 2023 Bright SCIdea Challenge, we caught up with Team Eolic Wall, the Audience Winner for the 2022 competition.

Eolic Wall was always a nice fit for Bright SCIdea. The team spotted a problem in our renewable energy mix and came up with a scientific business idea to solve it. They saw that wind energy is generated for the public, but it isn’t generated by the public. This stands in bright contrast to solar power generation.

‘Today, 40% of all installed capacity in solar energy is based on solar panels installed on the rooftops of home and corporate buildings,’ said Alfredo Calle, founder of Eolic Wall. ‘The remaining 60% correspond to solar farms.’

Eolic wall
Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.

The wind industry is different. ‘Only 1% of the installed capacity comes from households and businesses,’ he added. ‘That is, 99% of all installed capacity in the world comes from wind farms. That sort of concentration is a problem that hampers the energy transition.’

Calle believes this disparity hampers the move from fossil fuel dependency to clean, renewable energy. For many, micro-generation is key. We need to put power – renewable power – in the hands of the people. His idea is to make wind energy available in the home, just as solar exists on roofs everywhere.

The scale of this task is daunting. It turns out there’s a reason why we don’t all have wind turbines bolted onto our homes. The problem, Calle argues, is that a windmill must be large to be efficient.

 

He believes the Eolic Wall could change that – that this wall-mounted wind turbine is efficient enough to power our homes and offices.

‘We have created a technology that not only doubles wind speed to harvest more power from the same wind resources, but also has a wind turbine that works with magnetic levitation to almost eliminate any friction.’


From applicant to finalist

So, how did a team based out of the National University of Engineering in Peru and Universidade Estadual Paulista in Brazil end up competing for the £5,000 first prize in the Bright SCIdea final?

Chance. Fortune. Happenstance. Calle and his colleagues came upon Bright SCIdea through a social media post that immediately captured their attention.

Eolic Wall 

‘We thought that the Eolic Wall was ideal for Bright SCIdea because of the huge positive impact that this technology could have,’ he said, ‘and also because it perfectly fit into Bright SCIdea’s thesis of supporting ideas in the intersection of business, innovation and science.’

Applying was simple, although the business plan submission was intimidating at first. However, like all BrightSCIdea applicants they received coaching, and their brainchild found form.

‘The key driver to overcome that challenge was not to miss any training sessions and tutorials,’ Calle said. ‘The good news is that after going through the whole process you feel that everything was worthwhile. No pain, no gain.’

Check out fellow 2022 finalist Klara Hatinova from Team Happy BioPatch in conversation with the Periodic Fable podcast.

Science & Innovation

An Artificial Intelligence tool that could change the way we treat heart disease wowed the judges at this year’s Bright SCIdea competition. Now that the dust has settled, we asked Raphael Peralta, from the winning CardiaTec team, about winning the competition, the need for this technology, and tips for future participants. After winning this prestigious competition and coming away with the £5,000 first prize, the future is bright for co-founders Raphael Peralta, Thelma Zablocki and Namshik Han. So, how do they reflect on the story so far?

Bright SCIdea 2022 - Team CardiTec

Team CardiaTec (UK)

Tell us about CardiaTec
Cardiovascular disease is the world’s leading cause of death, and affects countless lives. Despite this, investment and innovation within the space has been severely stagnated, especially in comparison to fields such as oncology. The current treatment landscape remains unchanged, and treatments are most often prescribed in a standardised, one-size-fits-all approach. However, people are fundamentally different, and as shown by the Covid-19 pandemic, similar groups of people can experience a disease in a significantly different manner, and as such it is very important to understand biological processes at a patient level to produce effective therapeutic outcomes.

CardiaTec is leveraging artificial intelligence to structure and analyze large scale biological data that spans the full multiomic domain. This allows for a comprehensive understanding of disease pathophysiology to better develop novel and effective therapeutics for cardiovascular disease.

Casting your mind back to the moment you were announced the winner of Bright SCIdea 2020, what were your initial thoughts?
We thought we had a good opportunity to win it, but obviously when it was announced, it was a great feeling. Winning this competition is a further validation that what we are generating has real world value.

It was a great judging panel, with a breadth of experience across drug discovery and the pharmaceutical industry. We were up against immense global competition and the fact that we won shows that there’s a need for novel innovation in the cardiovascular space to ultimately drive the development of new therapeutics that are going to help change people's lives.

How did you think of the idea? Was there a ‘eureka’ moment?
The way the initial idea came about was through the identification that the cardiovascular space had a massive unmet need compared to other spaces such as oncology. I had worked with a cardiovascular company doing some consulting work and this is where it came to light.

In combination, multiomic techniques are becoming increasingly accessible in line with technological developments, which have made processes of next generation sequencing and proteomic profiling increasingly cheaper. These processes generate large amounts of data, which then lend themselves to applications of machine learning to derive biologically meaningful insights. These process, although becoming increasingly familiar in areas such as oncology, are highly underrepresented in cardiovascular disease, and thus there spans opportunity to develop completely unique and novel insights.

How does the technology work?
Here, CardiaTec uses data across genomics, epigenomics, transcriptomics, proteomics, and metabolomics, to generate novel biological insights with the help of AI and machine learning applications. Taking these many ‘omics’ into consideration is what defines a ‘multiomic’ approach. Biology is complex, and trends require full multiomic assessment to truly understand where dysregulation of specific processes is occurring, to then inform the best means of intervention.

CardiaTec is developing a platform, which with time will grow to become one of the most comprehensive foundations of cardiovascular disease biology. Results and outcomes are iteratively incorporated into the model, and new hypotheses are tried and tested across a range of pre-clinical settings. Collectively, CardiaTec aims to generate novel drug targets that can be used to help reduce the burden of disease in current and future patient population.

In the process of getting to the final, there were several opportunities to engage with entrepreneurs, investors, business leaders, and experts in intellectual property (IP). Can you share key takeaways from these sessions?
One of the most important things you can do is speak to people. Every business starts from an idea. As you start developing, you change and refine the business model. We take every chance to engage with people who have industry experience. It’s really important that we take the advice of these people on board; this is especially true in the field of biotechnology where you take risks across the technology side, the commercial side, and the biological side. It takes a lot of experience to mitigate those risks.

How difficult has it been taking that idea and turning it into a viable business proposition?
Thelma and I came out of the MPhil in Bioscience Enterprise at the University of Cambridge. It gave us this really strong foundation to start building. We also had the biological knowledge from our previous degrees. This framework, where we had key opinion leaders and great people in the field with whom we could bounce ideas off, was the first step. We saw that the idea was really positive and was received well by a lot of people. So, we thought: ‘we’re onto something’.

When building a biotech company, if you’re not passionate about it and don’t want to spend a lot of your time dedicated to the project, then it’s not going to take off. You need to be there to make changes, and really embrace and understand where you believe it’s going to go in line with the advice you've been given and the insights that you have generated.

We’re not only interested in understanding the intricate nature of biology. We’re also interested in how this has real life application in changing people’s lives. Every person we speak to has been affected in some way by cardiovascular disease.

I noticed that your presentation was really polished. Do you have any tips for people presenting in the final?
We’ve presented a lot of times so I think practice makes perfect. With a presentation, you need to be able to tell a story. It’s all about the storyline and building that image. You have to take care and be diligent in the process. Take time to make sure everything is structured correctly and that the story flows. Don’t be afraid to present to a lot of people who will give you advice. Take the time to make the amendments and run it through again and again, and see what the response is. So, take your time on the presentation to get your story across.

You were both very calm when the judges’ questions came. How did you prepare for these questions?
Out of this Cambridge network, the people we spoke to all asked the right questions. You see the pattern of these questions. They all want to know similar things. So, once we identified that pattern, we wrote down the questions that were important from our conversations and we practiced responses to these questions, which were by this point, fully embedded into the company’s business model; which then lends itself to an insightful, actionable response.

How are you going to use the £5,000 prize money and what’s next?
We’ll put the prize money towards refining of some of our technology. In terms of what’s next, Thelma (Zablocki), Namshik (Han), and I are dedicated to this company. We want to see it through and eventually make a drug that ends up reaching patients. This will take a long time.

To see that in the real world, where someone’s getting prescribed a drug that you discovered would be incredible.

>> For more on this year’s Bright SCIdea final, go to: https://www.soci.org/news/2022/3/bright-scidea-final-2022.